Analyst views Invenra and Exelixis partnership to provide new anti-cancer therapies

Biotech start-up Invenra recently announced a partnership collaboration with fellow USA-based Exelixis (Nasdaq: EXEL) to develop multi-specific antibodies as cancer therapies.

Their partnership agreement allows Exelixis to expand its current small molecule pipeline to create a biologics pipeline able to provide new anti-cancer therapies, says data and analytics company GlobalData.

The partnership combines the biological insight, clinical development, and commercialization expertise of Exelixis with the innovative platforms and biologics expertise of Invenra. This will facilitate the identification and optimization of lead candidates leading to the manufacture of multi-specific therapies, which include immunotherapies. Exelixis will be able to create an innovative pipeline past the commercially available compounds of cabozantinib and cobimetinib.